You are here

Erythropoietic Therapy: Dosing Patterns and Calculated Cost Assessment for Pre-dialysis Chronic Kidney Disease Patients In a Managed Care Setting

John J. Barron, PharmD, W. Daniel Grochulski, PhD, Samir H. Mody, PharmD, MBA, Brahim K. Bookhart, MBA, MPH, and R. Scott McKenzie, MD
In a comparison of two erythropoiesis-stimulating agents, drug costs were found to be lower for epoetin alfa than for darbepoetin alfa.